A
Avid Radiopharmaceuticals
Molecular imaging agents for detecting and monitoring chronic human diseases
About Avid Radiopharmaceuticals
Avid Radiopharmaceuticals operates as a key player in the field of molecular imaging, focusing on the development of agents to detect and monitor chronic diseases. The company was established in late 2004 by Dr. Daniel M. Skovronsky, who leveraged his background as the former Scientific Director at the University of Pennsylvania's Center for Neurodegenerative Disease Research to address a critical gap in medical diagnostics. Dr. Skovronsky, who holds an M.D. and Ph.D. from the University of Pennsylvania, founded the company to create a diagnostic tool for Alzheimer's disease that could be used on living patients, moving beyond the traditional post-mortem diagnosis.
A significant milestone in the company's history was its acquisition by Eli Lilly and Company in December 2010. The deal involved an upfront payment of $300 million, with an additional potential of $500 million contingent on regulatory and commercial milestones. Following the acquisition, Avid Radiopharmaceuticals became a wholly-owned subsidiary of Lilly, continuing its operations from Philadelphia.
The company's core business revolves around the development and commercialization of radiopharmaceuticals used with Positron Emission Tomography (PET) scans. Its flagship product is Amyvid™ (Florbetapir F 18), a radioactive diagnostic agent designed to estimate the density of beta-amyloid plaques in the brain. These plaques are a defining pathology of Alzheimer's disease. Amyvid works by binding to these amyloid plaques, which can then be visualized in PET scan images. A negative scan indicates few to no plaques, reducing the likelihood that cognitive impairment is due to Alzheimer's. Conversely, a positive scan shows a moderate to frequent amount of plaque, which, while characteristic of Alzheimer's, can also be present in other neurological conditions or in cognitively normal older adults. Therefore, the product serves as an adjunct diagnostic tool for physicians evaluating patients with cognitive decline.
Amyvid received FDA approval in April 2012 and subsequently gained marketing authorization in the European Union in early 2013. The company also has a broader diagnostics development platform exploring agents for other conditions, including Parkinson's disease and diabetes. Its business model appears to be centered on the revenue generated from the sale of its imaging agents to healthcare providers and its use in clinical trials for Alzheimer's treatments being developed by other pharmaceutical firms. Avid provides its products and support for major academic clinical trials, such as the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 127
- Open positions
- None listed
- Dealroom signal
- 59.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Personal Health, Diabetes, Biotechnology, Oncology, Health Diagnostics, Hard Tech, Radiopharmaceuticals, DT and LS, science-based
- Technology
- Big Data
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Avid Radiopharmaceuticals is 240 monthly website visits, up 9.1% over the last three months. Avid Radiopharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Avid Radiopharmaceuticals in the Philadelphia ecosystem
The Avid Radiopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
BioAdvance
Series A1 investor entered at this stage
- PVPfizer Ventures
Series B and later6 investors entered at this stage
AllianceBernstein
Safeguard Scientifics- RGRK Ventures Group
Lilly Ventures
Alta Partners
Osage University Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avid Radiopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avid Radiopharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








